Barclays PLC Ultragenyx Pharmaceutical Inc. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Barclays PLC holds 62,913 shares of RARE stock, worth $3.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,913

Previous 118,773 47.03%

Holding current value

$3.42 Million

Previous $5.55 Million 53.36%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $2.09 Million - $2.88 Million	-55,860 Reduced 47.03%	62,913 $2.59 Million
Q1 2024 May 15, 2024	SELL	$43.02 - $53.69 $2.06 Million - $2.58 Million	-47,969 Reduced 28.77%	118,773 $5.55 Million
Q4 2023 Feb 15, 2024	BUY	$31.73 - $49.19 $1.46 Million - $2.27 Million	46,049 Added 38.15%	166,742 $7.97 Million
Q3 2023 Nov 07, 2023	BUY	$34.92 - $46.66 $647,835 - $865,636	18,552 Added 18.16%	120,693 $4.3 Million
Q2 2023 Aug 03, 2023	BUY	$37.35 - $52.15 $391,203 - $546,219	10,474 Added 11.43%	102,141 $4.71 Million
Q1 2023 May 04, 2023	SELL	$36.99 - $48.71 $1.22 Million - $1.6 Million	-32,920 Reduced 26.42%	91,667 $3.68 Million
Q4 2022 Feb 13, 2023	BUY	$33.72 - $46.33 $303,378 - $416,831	8,997 Added 7.78%	124,587 $5.77 Million
Q3 2022 Nov 03, 2022	BUY	$39.96 - $66.14 $3.82 Million - $6.32 Million	95,515 Added 475.79%	115,590 $4.79 Million
Q2 2022 Aug 12, 2022	BUY	$45.8 - $85.4 $21,663 - $40,394	473 Added 2.41%	20,075 $1.2 Million
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $238,101 - $323,083	-3,828 Reduced 16.34%	19,602 $1.42 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $1.38 Million - $1.64 Million	18,715 Added 396.92%	23,430 $1.97 Million
Q3 2021 Nov 09, 2021	SELL	$77.92 - $102.4 $1.53 Million - $2.01 Million	-19,665 Reduced 80.66%	4,715 $425,000
Q2 2021 Aug 13, 2021	SELL	$92.19 - $115.71 $4.36 Million - $5.47 Million	-47,296 Reduced 65.99%	24,380 $2.33 Million
Q1 2021 May 13, 2021	BUY	$106.9 - $167.73 $5.15 Million - $8.08 Million	48,152 Added 204.69%	71,676 $8.16 Million
Q4 2020 Feb 11, 2021	SELL	$84.4 - $177.39 $6.25 Million - $13.1 Million	-74,107 Reduced 75.91%	23,524 $3.26 Million
Q3 2020 Nov 12, 2020	BUY	$72.98 - $90.0 $4.61 Million - $5.68 Million	63,161 Added 183.23%	97,631 $8.03 Million
Q2 2020 Aug 12, 2020	SELL	$46.91 - $78.22 $5.5 Million - $9.18 Million	-117,302 Reduced 77.29%	34,470 $2.7 Million
Q1 2020 May 13, 2020	BUY	$33.8 - $62.9 $1.3 Million - $2.43 Million	38,561 Added 34.06%	151,772 $6.74 Million
Q4 2019 Feb 10, 2020	BUY	$36.08 - $45.83 $3.11 Million - $3.95 Million	86,164 Added 318.57%	113,211 $4.84 Million
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $352,197 - $522,992	-8,287 Reduced 23.45%	27,047 $1.16 Million
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $641,033 - $867,781	11,670 Added 49.32%	35,334 $2.24 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $693,738 - $1.21 Million	17,400 Added 277.78%	23,664 $1.64 Million
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $816,106 - $1.62 Million	-20,985 Reduced 77.01%	6,264 $273,000
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $1.17 Million - $1.46 Million	16,246 Added 147.65%	27,249 $2.08 Million
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $29,221 - $51,356	-602 Reduced 5.19%	11,003 $846,000
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $116,233 - $153,439	2,622 Added 29.19%	11,605 $592,000
Q4 2017 Feb 14, 2018	BUY	$43.54 - $57.32 $243,562 - $320,648	5,594 Added 165.06%	8,983 $416,000
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $168,738 - $224,758	3,389	3,389 $180,000

Others Institutions Holding RARE

# of Institutions

287

Shares Held

88.1M

Call Options Held

505K

Put Options Held

198K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.81B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account